Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Genmab ( (GMAB) ) is now available.
On May 21, 2025, Genmab A/S filed a report with the SEC detailing updates to their Articles of Association, which include authorizations for capital increases and the issuance of warrants and convertible debt instruments. These changes are intended to support the company’s growth and operational flexibility by allowing them to raise capital through new share issuances and convertible debt, potentially impacting shareholder value and market positioning.
The most recent analyst rating on (GMAB) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab exhibits strong financial performance with consistent profitability and low leverage. The company’s robust pipeline and strategic investments support future growth. However, technical analysis indicates neutral momentum, and dependency on key products introduces some risk.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is a Danish biotechnology company engaged in medical research, production, and sale of related products. The company is focused on the development of antibody therapeutics for the treatment of cancer and other serious diseases.
Average Trading Volume: 1,500,398
Technical Sentiment Signal: Sell
Current Market Cap: $12.29B
For an in-depth examination of GMAB stock, go to TipRanks’ Stock Analysis page.